Skip to main content
Figure 1 | Critical Care

Figure 1

From: Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study

Figure 1

Study flowchart. Patients were randomly assigned in different anticoagulation regimens (unfractioned heparin [UFH] versus UFH + tirofiban), separated according to the concomitant therapy with or without intra-aortic balloon pump (IABP). Furthermore, the concomitant antiplatelet therapy and the number of patients included in each subgroup were added. Exclusion criteria include cardiopulmonary resuscitation, suspected concomitant sepsis defined by haemodynamic criteria (reduced systemic vascular resistance), a platelet count of less than 100 × 109/L, or major bleeding signs (one patient retroperitoneal and one patient gastric haemorrhage). aPTT, activated partial thromboplastin time.

Back to article page

Critical Care

ISSN: 1364-8535